TGA certification for Ind-Swift Labs
Chandigarh, Mar 23 (UNI) Leading pharma Ind-Swift Laboratories Ltd has achieved an important milestone by obtaining the Therapeutic Goods Administration (TGA) certification from the Australian Common Wealth Department of Health and Ageing for its manufacturing facility for the 1.18 billion dollar drug 'clarithromycin'.
Describing it as'' a significant achievement'' Mr V K Mehta, joint managing Director of the company said here today the company is focusing on the regulated markets for its growth and the TGA certification will leverage the company's intrinsic potential and place it at par with the other leading players in the industry.
Ind-Swift Laboratories is one of the largest manufacturers of clarithromycin in the world and enjoys 30 to 33 per cent of the world market share for this drug.
The Australian Department has recommended that ''the company complies with the requirement of the Australian Code of Good Manufacturing Practice for medicinal products, for the range of products to be supplied to Australia''.
The company has launched four new Active Pharmaceuitical ingrdients (APIS) which include Letrozole (Aromtase Inhibitor), Quetiapine Fumerate (Anti-Psychotic), Aripiprazole (Anti-Pshycotic) and Ropinirole (Parkinsons Disease).
Mr Mehta said the company had recently inked a joint venture with an Iranian Company. The joint venture will primarily focus on manufacturing of APIs in Iran and its marketing in the Middle East and partS of Europe.
Besides the main manufacuring facilities situated at Derabassi in Punjab, the company's other facility Jammu is primarily focused on manufacturing of API for the domestic market.
UNI HS BP SD VC1540